(2,5-dioxoimidazolidin-I-yl)-N-hydroxy-a cetamides as metalloproteinase inhibitors

Details for Australian Patent Application No. 2006326256 (hide)

Owner Medivir AB

Inventors Parkes, Kevin; Xu, Ming Hua; Lin, Guo Qiang; Sun, Piaoyang; Samuelsson, Bertil; Wallberg, Hans; Lei, Xin Sheng; Johnson, Tony

Agent Davies Collison Cave

Pub. Number AU-B-2006326256

PCT Pub. Number WO2007/068474

Priority 05112144.0 14.12.05 EP

Filing date 13 December 2006

Wipo publication date 21 June 2007

Acceptance publication date 3 November 2011

International Classifications

C07D 233/74 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 233/76 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 233/78 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

Event Publications

26 June 2008 PCT application entered the National Phase

  PCT publication WO2007/068474 Priority application(s): WO2007/068474

3 November 2011 Application Accepted

  Published as AU-B-2006326256

1 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006326257-(1-aza-bicyclo[3.3.1] non4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amin es as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders

2006326255-Organic compounds